Saturday, February 7, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Analysis

BASF Faces Investor Skepticism Despite Major Business Unit Sale

Robert Sasse by Robert Sasse
October 15, 2025
in Analysis, Chemicals, DAX, Mergers & Acquisitions
0
BASF Stock
0
SHARES
13
VIEWS
Share on FacebookShare on Twitter

BASF finds itself navigating conflicting market signals as the chemical giant executes a significant divestiture while simultaneously facing a downgrade from financial analysts. The German conglomerate’s planned sale of its coatings operation for €7.7 billion has been overshadowed by Berenberg Bank’s decision to slash its rating on the company’s shares to “Sell.”

Analyst Concerns Deepen Despite Strategic Move

Berenberg Bank has taken a decidedly bearish stance on BASF, not only downgrading the stock from “Hold” to “Sell” but also implementing a substantial reduction in its price target. The bank now projects a share value of €37, down significantly from its previous €44 estimate.

Market experts at Berenberg point to several persistent challenges:

  • Ongoing weakness in operational demand continues to pressure business performance
  • Petrochemical margins remain constrained across the industry
  • Agricultural cycle projections appear increasingly unfavorable
  • Further reductions to consensus earnings estimates are anticipated

This pessimistic assessment arrives at an inopportune moment for BASF, which had hoped to demonstrate strategic strength through its recent business transaction.

€7.7 Billion Transaction with Carlyle Group

In a deal structured with private equity firm Carlyle and the Qatar Investment Authority, BASF has agreed to divest its coatings business while retaining a 40% stake in the operation. The transaction will deliver approximately €5.8 billion in immediate cash proceeds to the chemical company.

Should investors sell immediately? Or is it worth buying BASF?

The business unit, which generated €3.8 billion in revenue during 2024, commanded a robust valuation in the agreement. The purchase price implies an enterprise value to EBITDA multiple of approximately 13 times, reflecting strong investor interest in the coatings segment.

Operational Weakness Overshadows Strategic Initiatives

Financial performance metrics reveal underlying challenges within BASF’s operations. The Industrial Solutions division reported a 5% revenue decline to €4.4 billion during the first half of the year, while EBITDA contracted more sharply, falling 11% to €668 million.

These figures highlight the structural headwinds affecting the broader chemical sector, with BASF experiencing their full impact.

From a technical perspective, BASF shares appear oversold, with the Relative Strength Index registering just 26 points. This indicates significant selling pressure in recent trading sessions. The current share price of €41.78 represents a 22.6% decline from the 52-week peak of €53.98.

The fundamental question for investors remains whether the coatings division sale represents a strategic masterstroke that will address core business challenges, or merely provides temporary financial relief without solving structural issues. The company’s third-quarter results, scheduled for release on October 21, may offer initial indications of which scenario will prevail.

Ad

BASF Stock: Buy or Sell?! New BASF Analysis from February 7 delivers the answer:

The latest BASF figures speak for themselves: Urgent action needed for BASF investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 7.

BASF: Buy or sell? Read more here...

Tags: BASF
Robert Sasse

Robert Sasse

About Dr. Robert Sasse Accomplished economist, entrepreneur, and profound expert in financial markets. Dr. Robert Sasse holds a doctorate in economics and combines academic rigor with practical entrepreneurial experience. His deep expertise in economic relationships and unwavering conviction for a free-market liberal economic order drives his mission to provide investors with well-founded knowledge and guidance.
Areas of Expertise:
  • Economic Theory and Practice
  • Free-Market Economics
  • Entrepreneurship and Business Strategy
  • Investment Philosophy
Dr. Sasse's unique combination of academic knowledge and real-world business experience enables him to provide investors with comprehensive insights that bridge theory and practice.

Related Posts

Universal Insurance Stock
Analysis

Universal Insurance Maintains Quarterly Payout Amid Sector Headwinds

February 7, 2026
Diginex Stock
Blockchain

Diginex Enters Critical Implementation Phase Following Strategic Moves

February 7, 2026
Deluxe Stock
Analysis

Deluxe Stock Gains Momentum on Successful Fintech Transition

February 6, 2026
Next Post
Hensoldt Stock

Hensoldt Shares Slide Despite Major Drone Partnership Announcement

Thyssenkrupp Stock

Billion-Dollar Stakes as Thyssenkrupp Marine Unit Nears Market Debut

Covestro Stock

Covestro Acquisition Nears Final Approval as Major Investors Position Themselves

Recommended

CRWD stock news

Tower Research Capital LLC TRC Demonstrates Unwavering Confidence in CrowdStrike Holdings as Cybersecurity Leader

2 years ago
Efficiently Reporting an Absence on WalmartOne: A Step-by-Step Guide for Employees

Beacon Announces Interim Chief Financial Officer

2 years ago

Alaska Airlines Boeing 737 Investigation Missing Bolts and Safety Measures

2 years ago

Impressive Financial Performance for Kiniksa Pharmaceuticals

2 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Viking Therapeutics: Upcoming Financial Report to Guide Investor Sentiment

Diginex Enters Critical Implementation Phase Following Strategic Moves

Deluxe Stock Gains Momentum on Successful Fintech Transition

Hydrofarm Holdings: Q4 2025 Earnings Report Date Approaches

Northeast Bancorp Reports Robust Loan Growth Amid Strong Quarterly Performance

Vir Biotechnology’s 2026 Pipeline: A Year of Pivotal Clinical Data

Trending

Universal Insurance Stock
Analysis

Universal Insurance Maintains Quarterly Payout Amid Sector Headwinds

by Rodolfo Hanigan
February 7, 2026
0

Universal Insurance Holdings has reaffirmed its commitment to shareholder returns, declaring its regular quarterly dividend despite a...

Embecta Stock

Embecta’s Q1 Performance Outpaces Analyst Forecasts

February 7, 2026
Camping World Stock

Camping World’s New Leadership Faces First Major Test

February 7, 2026
Viking Therapeutics Stock

Viking Therapeutics: Upcoming Financial Report to Guide Investor Sentiment

February 7, 2026
Diginex Stock

Diginex Enters Critical Implementation Phase Following Strategic Moves

February 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Universal Insurance Maintains Quarterly Payout Amid Sector Headwinds
  • Embecta’s Q1 Performance Outpaces Analyst Forecasts
  • Camping World’s New Leadership Faces First Major Test

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com